Niraparib for Glioblastoma
Phase-Based Progress Estimates
Effectiveness
Safety
Glioblastoma+2 More
Niraparib - DrugEligibility
18+
All Sexes
What conditions do you have?
Select
Eligibility
18+
All Sexes
What conditions do you have?
Select
Study Summary
This trial is testing a new cancer treatment that uses both a drug and electric fields to treat brain tumors.
Eligible Conditions
- Glioblastoma
- GBM
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 5 Secondary · Reporting Duration: When termination of the study or 5 years after removal from protocol therapy, whichever occurs first.
Year 5
Disease control, defined as achievement of either CR, PR, or SD, as defined by modified Response Assessment in Neuro-Oncology (mRANO) criteria.
Duration of disease control.
Number of AEs (Adverse Events)
Objective radiographic response (ORR)
Objective response rate (ORR) associations.
Overall survival (OS)
Overall survival (OS) associations
Progression-free survival (PFS)
Progression-free survival (PFS) associations
Trial Safety
Safety Progress
This is further along than 68% of similar trials
Side Effects for
Stage 1 (Cohort 2): Niraparib + Pembrolizumab
57%Nausea
52%Decreased appetite
48%Anaemia
48%Constipation
43%Fatigue
38%Dyspnoea
24%Oedema peripheral
24%Vomiting
24%Stomatitis
24%Platelet count decreased
19%Insomnia
19%Blood alkaline phosphatase increased
19%Arthralgia
19%Pruritus
14%Pneumonia
14%Diarrhoea
14%Cough
14%Pain
14%Chills
14%Upper respiratory tract infection
14%Weight decreased
14%Neutrophil count decreased
14%Dysgeusia
14%Back pain
14%Muscular weakness
10%Depression
10%Erythema
10%Vision blurred
10%Pleural effusion
10%Atrial fibrillation
10%Neuropathy peripheral
10%Haemorrhoids
10%Haemorrhoidal haemorrhage
10%Anxiety
10%Proctalgia
10%Oropharyngeal pain
10%Wheezing
10%Non-cardiac chest pain
10%Productive cough
10%Gait disturbance
10%Chest pain
10%Urinary tract infection
10%Hypophosphataemia
10%Aspartate aminotransferase increased
10%Dehydration
10%Blood creatinine increased
10%Hypokalaemia
10%Lymphocyte count decreased
10%Alanine aminotransferase increased
10%Rash maculo-papular
10%Pain of skin
10%Overdose
10%Hypothyroidism
5%Dysphonia
5%Sinus tachycardia
5%Angina pectoris
5%Neuroendocrine carcinoma of the skin
5%Gastrooesophageal reflux disease
5%Candida infection
5%Sepsis
5%Dizziness
5%Fall
5%Pulmonary embolism
5%Pneumonitis
5%Respiratory failure
5%Cardiac arrest
5%Pericardial effusion
5%Intestinal obstruction
5%Lactic acidosis
5%Diverticulitis
5%Lethargy
5%Headache
5%Cancer pain
5%Toxicity to various agents
5%Abdominal pain
5%Haematochezia
5%Nasal congestion
5%Asthenia
5%Pyrexia
5%Malaise
5%Hypomagnesaemia
5%Hyponatraemia
5%Amylase increased
5%Hepatic enzyme increased
5%Peripheral sensory neuropathy
5%Pain in extremity
5%Hyperhidrosis
5%Tachycardia
5%Contusion
5%Hypotension
5%Lipase increased
5%Syncope
5%Hyperglycaemia
Trial Design
2 Treatment Groups
Cohort B
1 of 2
Cohort A
1 of 2
Active Control
Experimental Treatment
30 Total Participants · 2 Treatment Groups
Primary Treatment: Niraparib · No Placebo Group · Phase 2
Cohort AExperimental Group · 2 Interventions: Niraparib, Optune · Intervention Types: Drug, Device
Cohort BActiveComparator Group · 3 Interventions: Planned surgical resection, Niraparib, Optune · Intervention Types: Procedure, Drug, Device
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Niraparib
FDA approved
Optune
2016
Completed Phase 1
~90
Trial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: when termination of the study or 5 years after removal from protocol therapy, whichever occurs first.
Who is running the clinical trial?
Tesaro, Inc.Industry Sponsor
55 Previous Clinical Trials
10,353 Total Patients Enrolled
NovoCure Ltd.Industry Sponsor
52 Previous Clinical Trials
4,516 Total Patients Enrolled
26 Trials studying Glioblastoma
2,588 Patients Enrolled for Glioblastoma
University of PennsylvaniaLead Sponsor
1,816 Previous Clinical Trials
41,115,063 Total Patients Enrolled
7 Trials studying Glioblastoma
168 Patients Enrolled for Glioblastoma
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:You have had a relapse of Crohn's disease.
You have a Karnofsky performance status of 60 or higher.
You have a life expectancy of at least 3 months.
Adequate hematologic parameters.
Patients must have measurable contrast-enhancing disease (defined by at least 1cm x 1cm) by magnetic resonance imaging (MRI) imaging within 28 days of starting study treatment.
You have a diagnosis of glioblastoma that is recurrent following radiation therapy
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Top Oncology Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments